top of page
Browse by category
Search
Most weight loss achieved using injectable obesity drugs can be maintained by switching to orforglipron
Most weight loss achieved using the injectable obesity drugs tirzepatide or semaglutide can be maintained by switching to daily oral orforglipron treatment, accord to research presented at the European Congress on Obesity in Istanbul, Turkey. The study is by Dr Louis J Aronne, Director of the Comprehensive Weight Control Center at Weill Cornell Medicine, New York, NY, and colleagues. While the efficacy of injectable therapies has been repeatedly proven in clinical trials, how
Lilly's oral GLP-1 orforglipron achieves average of 27.3 lbs weight loss at 72 weeks
Eli Lilly and Company has announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational...
Lilly's oral GLP-1 orforglipron consistent with injectable GLP-1 medicines
The topline Phase 3 results from Eli Lilly ACHIEVE-1 study, evaluating the safety and efficacy of orforglipron compared to placebo in...
Once-daily oral nonpeptide GLP-1-RA achieved up to 14.7% mean weight reduction at 36 weeks
Phase 2 data for orforglipron (12 mg, 24 mg, 36 mg or 45 mg), a nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, has...
Browse by tag
bottom of page